Page 51 - 2020Taiwan Food and Drug Administration Annual Report
P. 51
III. Reinforced bilateral medical interaction between Taiwan and Japan
TFDA and Japan collaboratively completed the “New Drug Review Scheme between
0+/: 30'$ DQG 7)'$ &'(´ LQ WR IXO¿OO WKH XUJHQW PHGLFDO QHHGV IRU ERWK FRXQWULHV
as well as the accessibility of medicines, establish a practical operation model for the new drug
review cooperation between two parties, enhance the participation of Taiwanese and Japanese
business operators and speed up the launch of new drugs from both countries. This is an
important milestone for Taiwan-Japan medical interaction and cooperation (Figure 3-5).
UI
'JHVSF cc 5IF +PJOU $POGFSFODF PG 5BJXBO BOE +BQBO PO .FEJDBM 1SPEVDUT 3FHVMBUJPO
IV. Conducted international conferences through the PIC/S platform
Taiwan held the “PIC/S Expert Circle Meeting on Control of Cross Contamination in Shared
Facilities” and once again was well recognized by all participants. At the same time, we interacted
with international experts to facilitate international cooperation and continue to facilitate the goal
of aligning Taiwan’s GMP regulations with international standards (Figure 3-6).
TU
'JHVSF cc5IF 1*$ 4 &YQFSU $JSDMF .FFUJOH PO $POUSPM PG $SPTT $POUBNJOBUJPO JO 4IBSFE
'BDJMJUJFT JO
49
